Circulation: Cardiovascular Quality & Outcomes

JANUARY 19, 2024

Background:Type 2 myocardial infarction (T2MI) and type 1 myocardial infarction (T1MI) differ with respect to demographics, comorbidities, treatments, and clinical outcomes. 3.48]), and diagnoses of COVID-19 (odds ratio, 1.74 [95% CI, 1.11–2.71]) T1MI and 53.5% T2MI; mean age, 79±10.3 years; 47% female).

Myocardial Infarction 40

Myocardial Infarction COVID-19 Medicare Hospital 40

Open Heart

JUNE 24, 2022

Introduction COVID-19 may lead to long-term endothelial consequences including hypertension, stroke and myocardial infarction. mm Hg higher BP ≥12 weeks after recovery, compared with a group without COVID-19. mm Hg higher BP ≥12 weeks after recovery, compared with a group without COVID-19.

Blood Pressure 52

Blood Pressure COVID-19 Myocardial Infarction Hypertension 52

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. To have a 25% to 30% reduction in heart failure hospitalizations is pretty clinically meaningful, but if you put it together with all-cause mortality, it was not a positive study for our primary endpoint.”

Heart Attack 98

Heart Attack Heart attacks Heart Failure Outpatient 98

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24, 24, being held in Atlanta, GA.

Heart Attack 81

Heart Attack Heart attacks Heart Failure Outcomes 81

Heart BMJ

MARCH 12, 2024

The primary outcome was a composite of all-cause mortality, new myocardial infarction or hospitalisation for heart failure at 12 months. Results The trial was discontinued early by the funder due to slow recruitment during the COVID-19 pandemic. The length of hospital stay was reduced with a very early IS (3.9

COVID-19 52

COVID-19 Myocardial Infarction Heart Failure Outcomes 52

Dr. Smith's ECG Blog

NOVEMBER 12, 2020

This is a 30-something healthy patient presented with COVID pneumonia who presented to the ED. An elevated troponin in a COVID patient confers about 4x the risk of mortality than a normal one. Beware elevated troponins in COVID patients. He was moderately hypoxic. There is minimal, probably normal STE in V2-V6. 3–8 Shi et al.

Cardiac Arrest 52

Cardiac Arrest COVID-19 Myocardial Infarction Cardiogenic Shock 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52